Tyrosine Kinase Inhibitors Market Size to Grow by USD 19.07 Bn, North America to Account for 38% of Market Growth - Technavio

NEW YORK, Oct. 20, 2022 /PRNewswire/ -- The tyrosine kinase inhibitors market size is expected to grow by USD 19.07 billion from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 7.73% during the forecast period, according to Technavio. The market has been segmented by product (RTKIs and nRTKIs) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

Make confident decisions using the insights and analysis provided by Technavio. Request a FREE PDF Sample Report

By geography, North America will account for 38% of the market's growth during the forecast period. Moreover, market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key countries for the tyrosine kinase inhibitors market in North America. The growth of this market is attributed to factors such as the high prevalence rate of cancer and the high unmet need for effective treatment. According to the National Program of Cancer Registries (NPCR) carried out by the Centers for Disease Control and Prevention (CDC), more than 28.5 million invasive cancer cases have been diagnosed in the last two decades.

By product, the RTKIs segment will be the largest contributor to market growth during the forecast period. These therapeutics are used in the treatment of various diseases. The increasing sales of these drugs, along with a strong pipeline with late-stage molecules and recent drug approvals, are expected to drive the growth of this segment during the forecast period. Drugs such as EYLEA, AVASTIN, and LENVIMA generated significant sales in 2021. For instance, EYLEA generated USD 1,612 million from annual sales in 2021, while AVASTIN generated USD 7,866 million in the same year.

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report

The presence of patient assistance programs is driving the tyrosine kinase inhibitors market. Many government and non-government organizations are focusing on providing financial and clinical assistance for the treatment of various cancer indications. Hence, many patients are availing the required treatment, which is increasing the patient base. Such programs also help patients in adhering to treatment regimens. These factors are supporting the growth of the global tyrosine kinase inhibitors market.

Get lifetime access to our Technavio Insights! Subscribe to our "Basic Plan" billed annually at USD 5000

Strategic alliances are a key trend in the tyrosine kinase inhibitors market. The rising prevalence of various diseases has increased the demand for innovative therapeutics. Tyrosine kinase inhibitors therapeutics are used for the treatment of cancer and age-related diseases such as retinal vein occlusion. Hence, many companies are developing and marketing these drugs. They are also entering into strategic alliances, partnerships, and collaborations to expand their geographical reach, expand their product portfolios, and get a better return on investment. These factors are supporting the growth of the market.

Identify key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. Buy Now to gain access to this information

Phosphoinositide 3-Kinase (PI3K) Inhibitors Market by Application and Geography - Forecast and Analysis 2022-2026: Recent approvals are supporting the phosphoinositide 3-kinase (PI3K) inhibitors market growth. Although many approved therapies are available for various types of blood cancer, the market experiences a huge unmet need for their treatment. Currently, many chemotherapy drugs are dominating the treatment landscape for several types of cancer.

BRAF Kinase Inhibitors Market by Product and Geography - Forecast and Analysis 2022-2026: The high target affinity and specificity of BRAF kinase inhibitors are driving market growth. BRAF kinase inhibitors with proven efficacy in oncology applications are developed as suitable solutions for cancer treatments. They are the most foreseen small molecule targeted therapy drugs for the treatment of carcinomas.

Browse Pharmaceuticals Market Reports

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Product

• 5.1 Market segments 
• Exhibit 24: Chart on Product - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Product - Market share 2021-2026 (%)

• 5.2 Comparison by Product 
• Exhibit 26: Chart on Comparison by Product
• Exhibit 27: Data Table on Comparison by Product

• 5.3 RTKIs - Market size and forecast 2021-2026
• Exhibit 28: Chart on RTKIs - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on RTKIs - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on RTKIs - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on RTKIs - Year-over-year growth 2021-2026 (%)

• 5.4 nRTKIs - Market size and forecast 2021-2026
• Exhibit 32: Chart on nRTKIs - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on nRTKIs - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on nRTKIs - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on nRTKIs - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Product 
• Exhibit 36: Market opportunity by Product ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 UK - Market size and forecast 2021-2026
• Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.11 Canada - Market size and forecast 2021-2026
• Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 84: Matrix on vendor position and classification

• 10.3 AbbVie Inc. 
• Exhibit 85: AbbVie Inc. - Overview
• Exhibit 86: AbbVie Inc. - Product / Service
• Exhibit 87: AbbVie Inc. - Key offerings

• 10.4 Amgen Inc. 
• Exhibit 88: Amgen Inc. - Overview
• Exhibit 89: Amgen Inc. - Product / Service
• Exhibit 90: Amgen Inc. - Key offerings

• 10.5 AstraZeneca Plc 
• Exhibit 91: AstraZeneca Plc - Overview
• Exhibit 92: AstraZeneca Plc - Product / Service
• Exhibit 93: AstraZeneca Plc - Key news
• Exhibit 94: AstraZeneca Plc - Key offerings

• 10.6 Bayer AG 
• Exhibit 95: Bayer AG - Overview
• Exhibit 96: Bayer AG - Business segments
• Exhibit 97: Bayer AG - Key offerings
• Exhibit 98: Bayer AG - Segment focus

• 10.7 Bristol Myers Squibb Co. 
• Exhibit 99: Bristol Myers Squibb Co. - Overview
• Exhibit 100: Bristol Myers Squibb Co. - Product / Service
• Exhibit 101: Bristol Myers Squibb Co. - Key offerings

• 10.8 C. H. Boehringer Sohn AG and Co. KG 
• Exhibit 102: C. H. Boehringer Sohn AG and Co. KG - Overview
• Exhibit 103: C. H. Boehringer Sohn AG and Co. KG - Business segments
• Exhibit 104: C. H. Boehringer Sohn AG and Co. KG - Key news
• Exhibit 105: C. H. Boehringer Sohn AG and Co. KG - Key offerings
• Exhibit 106: C. H. Boehringer Sohn AG and Co. KG - Segment focus

• 10.9 F. Hoffmann La Roche Ltd. 
• Exhibit 107: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 108: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 109: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 110: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 111: F. Hoffmann La Roche Ltd. - Segment focus

• 10.10 Johnson and Johnson 
• Exhibit 112: Johnson and Johnson - Overview
• Exhibit 113: Johnson and Johnson - Business segments
• Exhibit 114: Johnson and Johnson - Key news
• Exhibit 115: Johnson and Johnson - Key offerings
• Exhibit 116: Johnson and Johnson - Segment focus

• 10.11 Novartis AG 
• Exhibit 117: Novartis AG - Overview
• Exhibit 118: Novartis AG - Business segments
• Exhibit 119: Novartis AG - Key offerings
• Exhibit 120: Novartis AG - Segment focus

• 10.12 Pfizer Inc. 
• Exhibit 121: Pfizer Inc. - Overview
• Exhibit 122: Pfizer Inc. - Product / Service
• Exhibit 123: Pfizer Inc. - Key news
• Exhibit 124: Pfizer Inc. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 125: Inclusions checklist
• Exhibit 126: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 127: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 128: Research methodology
• Exhibit 129: Validation techniques employed for market sizing
• Exhibit 130: Information sources

• 11.5 List of abbreviations 
• Exhibit 131: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED